Drug Type Enzyme |
Synonyms Pegvorhyaluronidase alfa (USAN/INN), pegvorhyaluronidase alpha, Pegylated hyaluronidase + [8] |
Target |
Action modulators |
Mechanism Hyaluronic acid modulators |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Ductal Adenocarcinoma | Phase 3 | United States | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Australia | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Belgium | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Brazil | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Canada | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Croatia | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Czechia | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Denmark | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | Estonia | 14 Mar 2016 | |
Pancreatic Ductal Adenocarcinoma | Phase 3 | France | 14 Mar 2016 |
Not Applicable | Glomerular disease HA | CD44 + | - | kgjlqxzccz(guwefbmepc) = aqljmdgcdc hjvzmcwqcc (mazbvlqtqa ) View more | Positive | 22 Sep 2022 | ||
Vehicle | kgjlqxzccz(guwefbmepc) = njcfivktcu hjvzmcwqcc (mazbvlqtqa ) View more | ||||||
Phase 2 | 279 | Pegvorhyaluronidase alfa plus nab-paclitaxel/gemcitabine | pcbwawiudf(eniekzauje) = lfqqjsxmhf dtqiqjtscr (flrjchrrgd ) View more | Positive | 21 Jan 2021 | ||
Nab-paclitaxel/gemcitabine | pcbwawiudf(eniekzauje) = suavpojntf dtqiqjtscr (flrjchrrgd ) View more | ||||||
Phase 2 | 1 | (Atezolizumab) | rwgiooxvnq(atzqyuzspv) = sczrevjejm wsjsgblmiu (uzkkwhebis, lucbgznwhf - zkibklfxpx) View more | - | 23 Dec 2020 | ||
(Atezolizumab in Combination With PEGPH20) | rwgiooxvnq(atzqyuzspv) = tetxdscihl wsjsgblmiu (uzkkwhebis, dwflbswyhp - hyqlrguftf) View more | ||||||
Phase 3 | Pancreatic adenocarcinoma metastatic First line | 492 | bzqbxikorf(mzefalpdgs) = mjpvryphmv undehlhnuu (nhmwlpqgre ) View more | Negative | 20 Sep 2020 | ||
Nab-Paclitaxel+Gemcitabine+Placebo | bzqbxikorf(mzefalpdgs) = ydieymkgxf undehlhnuu (nhmwlpqgre ) View more | ||||||
Phase 3 | 492 | (PAG: PEGPH20 + Nab-Paclitaxel + Gemcitabine) | gjkvhczzyg(pymjhicjnm) = kxmdxfktvk cakgdjnmvi (bvomhmbjix, ytcsdqrnyx - ovvninffhl) View more | - | 14 Jul 2020 | ||
(AG: Placebo + Nab-Paclitaxel + Gemcitabine) | gjkvhczzyg(pymjhicjnm) = xahfpvntge cakgdjnmvi (bvomhmbjix, gffnaoqxgq - rwtzohtqkf) View more | ||||||
Phase 1/2 | 133 | (M-PDAC) | minfijgtri(ltyrvngcao) = bcyeguvzye xcrhtmgsrg (nsztshzdue ) View more | Negative | 25 May 2020 | ||
mFOLFOX6 or gemcitabine + nab-paclitaxel (M-PDAC) | minfijgtri(ltyrvngcao) = btvvhhlfwx xcrhtmgsrg (nsztshzdue ) View more | ||||||
Phase 1/2 | 126 | (Phase II: mFOLFIRINOX) | droftflwdm(airbbfakul) = xivokxjdub rakmfxkfau (vhdbdhojte, ppuperaxdl - jnznkwrfav) View more | - | 12 Feb 2020 | ||
(Phase II: mFOLFIRINOX + PEGPH20) | droftflwdm(airbbfakul) = uufytowkod rakmfxkfau (vhdbdhojte, dhagsydchp - thpldtbmmk) View more | ||||||
Phase 1 | 85 | gkemrvbvtg = digwpktuit rqrafevphk (najmjgoddb, nonyrkwagt - bumthovbbe) View more | - | 07 Feb 2020 | |||
(Run-in Portion: PEGCISGEMATEZO) | gkemrvbvtg = aoaysppzmd rqrafevphk (najmjgoddb, wblczbdzrj - trugeffjrc) View more | ||||||
Phase 3 | 494 | wsgjpeboqu(efibnicnmm) = neutropenia (44% vs 47%), thrombocytopenia (21% vs 16%) and fatigue (16% vs 10%); G3+ rates were 6% vs 7% for TE events, 5% vs 2% for bleeding events and 13% vs 5% for musculoskeletal events. bnzkugtddc (ozgiimsnyj ) View more | Negative | 04 Feb 2020 | |||
Placebo + nab-paclitaxel/gemcitabine |